- Trials with a EudraCT protocol (47)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
47 result(s) found for: Amylose.
Displaying page 1 of 3.
EudraCT Number: 2007-005287-27 | Sponsor Protocol Number: Doxycycline in ATTR | Start Date*: 2007-10-15 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: A Phase II Multicenter Pilot Study of the Safety and Efficacy of Doxycycline on disease progression in early to moderate ATTR amyloidosis | |||||||||||||
Medical condition: ATTR amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006037-13 | Sponsor Protocol Number: AC-003-IT | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: amyloidosis AL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001787-22 | Sponsor Protocol Number: AC-007-IT | Start Date*: 2012-05-02 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: An open-label, phase II study of Pomalidomide and Dexamethasone (PDex) for previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: Previously treated AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004150-16 | Sponsor Protocol Number: CL-503015 | Start Date*: 2014-06-19 | |||||||||||
Sponsor Name:A.T. Development Switzerland SARL | |||||||||||||
Full Title: International Open-Label Extension of the Phase 3 Study CL-503012 with KIACTA™ in Patients with AA Amyloidosis | |||||||||||||
Medical condition: AA Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021445-42 | Sponsor Protocol Number: HO104 | Start Date*: 2011-08-31 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: A multicenter, phase II study of bortezomib and dexamethasone as induction treatment followed by high dose melphalan (HDM) and autologous stem cell transplantation (SCT) in patients with de novo am... | |||||||||||||
Medical condition: AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006395-37 | Sponsor Protocol Number: BRD/06/055 | Start Date*: 2007-09-06 | |||||||||||
Sponsor Name:Joint UCLH and UCL Biomedical Research Unit | |||||||||||||
Full Title: A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would no... | |||||||||||||
Medical condition: The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014906-33 | Sponsor Protocol Number: UCL/08/0254 | Start Date*: 2010-09-17 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: A Pilot study of Response to Velcade combination chemotherapy in AL amyloidosis (REVEAL) | |||||||||||||
Medical condition: Systemic AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001962-13 | Sponsor Protocol Number: AC-016-IT | Start Date*: 2021-01-13 | |||||||||||
Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
Full Title: A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis | |||||||||||||
Medical condition: AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004001-32 | Sponsor Protocol Number: EMN27 | Start Date*: 2021-01-29 | |||||||||||
Sponsor Name: European Myeloma Network – EMN | |||||||||||||
Full Title: A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis | |||||||||||||
Medical condition: relapsed or refractory AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Ongoing) GR (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005455-15 | Sponsor Protocol Number: CACZ885D2304 | Start Date*: 2007-06-13 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A three-part multicenter study, with a randomized, doubleblind, placebo controlled, withdrawal design in Part II to assess efficacy, safety, and tolerability of ACZ885 (antiinterleukin-1β monoclona... | |||||||||||||
Medical condition: Muckle-Wells Syndrome (Autoinflammatory Disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004627-16 | Sponsor Protocol Number: 70233 | Start Date*: 2020-11-25 | |||||||||||
Sponsor Name:Helsinki University Hospital | |||||||||||||
Full Title: Clinical Validation of Quantitative Flutemetamol PET/CT in Cardiac Amyloidosis | |||||||||||||
Medical condition: Cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000276-23 | Sponsor Protocol Number: 201464 | Start Date*: 2016-12-06 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||||||||||||||||||
Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis | ||||||||||||||||||
Medical condition: Systemic amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002761-19 | Sponsor Protocol Number: OP201 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy | |||||||||||||
Medical condition: Patients with AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) NO (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002585-33 | Sponsor Protocol Number: PETAL | Start Date*: 2023-01-19 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A multi-center phase 3 study of 18F-florbetaben positron emission tomography/computed tomography (PET-CT) | ||||||||||||||||||
Medical condition: cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004367-22 | Sponsor Protocol Number: CACZ885D2306 | Start Date*: 2008-05-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, long-term safety and efficacy study of ACZ885 (anti-interleukin-1β monoclonal antibody) administered for at least 6 months in patients with the following cryopyrin-associated periodi... | |||||||||||||
Medical condition: The following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) BE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000776-34 | Sponsor Protocol Number: DFNS01 | Start Date*: 2011-06-07 | |||||||||||
Sponsor Name:Umea University | |||||||||||||
Full Title: THE EFFECT OF DIFLUNISAL ON FAMILIAL TRANSTHYRETIN AMYLOIDOSIS: An open label extension study of ”the diflunisal trial” (IND 68092), and an open label observational study on previously untreated p... | |||||||||||||
Medical condition: Familial transthyretin amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005236-25 | Sponsor Protocol Number: Dox/Urso | Start Date*: 2011-12-21 | |||||||||||
Sponsor Name:Umeå University | |||||||||||||
Full Title: A phase II multicenter pilot study of the safety and efficacy of Doxycycline/UrsoDeoxyCholicAcid on disease progression in ATTR amyloidosis | |||||||||||||
Medical condition: Transthyretin amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001621-41 | Sponsor Protocol Number: AC-011-IT | Start Date*: 2017-11-30 | |||||||||||
Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO | |||||||||||||
Full Title: A phase III randomized study of doxycycline and tauroursodeoxycholic acid (Doxy/TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by tra... | |||||||||||||
Medical condition: Cardiac amyloidosis caused by transthyretin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000686-40 | Sponsor Protocol Number: pulsar | Start Date*: 2023-05-04 | |||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | |||||||||||||
Full Title: Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis | |||||||||||||
Medical condition: cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004333-33 | Sponsor Protocol Number: EMN22/54767414AMY2005 | Start Date*: 2019-07-08 | |||||||||||
Sponsor Name:European Myeloma Network | |||||||||||||
Full Title: Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis | |||||||||||||
Medical condition: Patients with newly diagnosed stage 3B AL amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) NL (Ongoing) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.